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Abstract
Obstructive sleep apnea (OSA) is highly prevalent but very frequently undiagnosed. OSA is an 
independent risk factor for depression and cognitive impairment/dementia. Herein the authors 
review studies in the literature pertinent to the effects of OSA on the cerebral microvascular and 
neurovascular systems and present a model to describe the key pathophysiologic mechanisms that 
may underlie the associations, including hypoperfusion, endothelial dysfunction, and 
neuroinflammation. Intermittent hypoxia plays a critical role in initiating and amplifying these 
pathologic processes. Hypoperfusion and impaired cerebral vasomotor reactivity lead to the 
development or progression of cerebral small vessel disease (C-SVD). Hypoxemia exacerbates 
these processes, resulting in white matter lesions, white matter integrity abnormalities, and gray 
matter loss. Blood–brain barrier (BBB) hyperpermeability and neuroinflammation lead to altered 
synaptic plasticity, neuronal damage, and worsening C-SVD. Thus, OSA may initiate or amplify 
the pathologic processes of C-SVD and BBB dysfunction, resulting in the development or 
exacerbation of depressive symptoms and cognitive deficits. Given the evidence that adequate 
treatment of OSA with continuous positive airway pressure improves depression and 
neurocognitive functions, it is important to identify OSA when assessing patients with depression 
or cognitive impairment. Whether treatment of OSA changes the deteriorating trajectory of elderly 
patients with already-diagnosed vascular depression and cognitive impairment/dementia remains 
to be determined in randomized controlled trials.
Keywords
Obstructive sleep apnea; depression; cognitive impairment; intermittent hypoxemia; cerebral small 
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INTRODUCTION
By the year 2040, 82.3 million Americans, or 21.7% of the U.S. population, will be over 65 
years of age, and those aged 85 and older will triple from 6 million in 2013 to 14.6 million 
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in 2040.1 Consequently, late-life illnesses that cause significant morbidity and mortality will 
become an increasing public health problem. Such illnesses are frequently comorbid and 
may have a complex effect on disease progression, prognosis, and response to treatment. For 
example, epidemiologic studies and clinical trials have frequently illuminated the complex 
relationship between vascular disease, depression, and cognitive impairment. However, 
certain comorbidities are just now being recognized as clinically significant, such as the 
relationship between obstructive sleep apnea (OSA), depression, and dementia.
Currently, 22 million Americans suffer from sleep apnea, but estimates suggest that 80% of 
men and 93% of women with moderate to severe OSA have not been diagnosed.2 Although 
the relationships between OSA and depression or cognitive impairment/dementia are 
increasingly recognized as a serious public health concern, our understanding of the 
mechanisms that underlie these associations remains incomplete. It remains unclear how 
OSA is linked to depression and whether common pathways link OSA to depression and 
cognitive impairment/dementia.
Herein, we reviewed the literature pertinent to the effects of OSA on the cerebral 
microvascular and neurovascular systems and present a model describing the key 
pathophysiologic mechanisms that may underlie these associations, including 
hypoperfusion, endothelial dysfunction, and neuroinflammation. Further, we also discuss 
recommendations on how to identify OSA in patients with neuropsychiatric comorbidities 
and considerations for future research on OSA.
OBSTRUCTIVE SLEEP APNEA
Diagnosis
OSA is defined as repeated complete or partial collapse of the upper airway despite an effort 
to breathe during sleep. Polysomnography is the gold standard diagnostic test for OSA. 
Home testing with a portable monitor may be used to diagnose OSA in patients at high risk 
for moderate to severe OSA as part of a comprehensive sleep evaluation. According to the 
American Academy of Sleep Medicine criteria3 for scoring respiratory events, an apneic 
episode is defined as complete cessation of oronasal airflow for at least 10 seconds with a 
90% drop from baseline in oronasal airflow. A hypopneic episode is defined as incomplete 
airway obstruction for 10 seconds with a 30% drop from baseline in oronasal airflow and a 
4% decrease in oxyhemoglobin saturation, or a 50% drop of oronasal airflow and 3% 
decrease in oxyhemoglobin saturation. The frequency of apneas and hypopneas per hour of 
sleep defines the apnea-hypopnea index (AHI) and determines the severity of OSA: mild 
(AHI of 5–15), moderate (AHI of 15–30), or severe (AHI ≥ 30).
Epidemiology
OSA affects 24% of men and 9% of women of ages 30–60 years4 and 40%–60% of older 
adults (65+ years).5 The prevalence of moderate to severe OSA (AHI ≥ 15) is highest6 and 
the sex difference lowest in older adults. The prevalence of OSA in postmenopausal women 
not on hormonal replacement therapy is markedly increased, resulting in the reduced sex 
difference.6,7
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Risk factors for OSA include older age, male sex, a family history of OSA, and upper airway 
structural abnormalities (e.g., large neck girth and craniofacial abnormalities). OSA is also 
associated with vascular risk factors including obesity, hyperlipidemia, glucose intolerance, 
alcohol, and smoking. The impact of body mass index (BMI) on OSA severity decreases 
with age and is negligible by age 60.8 Hormone (especially progesterone) decreases in 
postmenopausal women lead to reduced ventilatory drive and a greater risk of developing 
OSA.9
Clinical Presentations
OSA presents with snoring, frequent awakening or gasping/choking during sleep, waking in 
the morning with headaches, and dry mouth. Some individuals experience excessive daytime 
sleepiness and fatigue, which impair cognitive functioning. Individuals with untreated OSA 
have triple the risk of a motor vehicle accident.10 In older people (aged 60+) OSA is not 
associated with sleepiness and loud snoring6 but may present a more complex clinical 
picture, with symptoms including frequent nocturnal urination, gait disturbance,11,12 
agitation,13 and postoperative delirium.14
OSA AND NEUROPSYCHIATRIC COMORBIDITIES
Depression
Prevalence—Epidemiologic studies have consistently demonstrated that OSA is 
associated with depression.15–18 In a cross-sectional study16 of 18,980 participants aged 15–
100 years, those with major depressive disorder were five times more likely to have OSA 
than the general population. Data from the Veterans Health Administration Beneficiary 
(from 1998 to 2001) indicated that the prevalence of mood disorder was significantly higher 
in individuals with OSA than those without OSA (22% versus 9%, p < 0.0001).19 
Furthermore, two longitudinal studies identified OSA as an independent risk factor for 
depression,17,18 in which the odds for developing depression were increased 2.0-fold (95% 
confidence interval [CI]: 1.4–2.9) in participants with mild OSA and 2.6-fold (95% CI: 1.7–
3.9) in those with moderate to severe OSA.
Treatment for OSA Ameliorates Depressive Symptoms—Changes in depressive 
symptoms with continuous positive airway pressure (CPAP) treatment suggest an association 
between OSA and depression. Although short-term (2–3 weeks), placebo-controlled CPAP 
studies did not find significant improvement in depressive symptoms,20,21 most evidence to 
date strongly suggests that CPAP benefits patients with mood disturbances.22–27 Most 
studies have focused on a middle-aged sample; less is known about depression-related 
benefits in elderly patients. A recently published study that included 224 elderly patients 
aged 70 or over with severe OSA (AHI ≥ 30) determined that at baseline, 52 patients 
(23.2%) had depression (Hospital Anxiety and Depression Scale on Depression score ≥ 11), 
38 patients (17%) had anxiety (Hospital Anxiety and Depression Scale on Anxiety score ≥ 
11), and 66 patients took antidepressants.28 After 3 months depressive (p < 0.001) and 
anxiety (p = 0.016) symptoms were significantly improved in the CPAP group (N = 115) 
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versus the no CPAP group (N = 109). Thus, CPAP was found to reduce depression and 
anxiety in elderly patients with severe OSA.
Another study examining CPAP and depression26 reported that in 228 patients who were 
CPAP treatment-compliant (>5 hours per night), including 71 elderly patients (aged 65+ 
years, 33.1%), 118 patients (51.8%) were taking antidepressants at baseline and continued 
their use throughout CPAP treatment. After 3 months of CPAP treatment, AHI reduced from 
46.7 (standard deviation [SD]: 27.4) to 6.5 (SD: 1.6), and the mean Patient Health 
Questionnaire-9 score decreased from 11.3 (SD: 6.1) to 3.7 (SD: 2.9) in the entire sample. 
The percentage of patients with depression (Patient Health Questionnaire-9 ≥ 10) at baseline 
dropped from 74.6% to 3.9% after 3 months of CPAP treatment.
One study included 20 patients with depression unresponsive to medication for over 6 
months who were also symptomatic for OSA.23 Seventeen (85%) were diagnosed with OSA 
(AHI ≥ 10) and received CPAP treatment. After 2 months of CPAP treatment the Hamilton 
Rating Scale for Depression and Beck Depression Inventory scores decreased from 16.7 to 
8.0 and 19.7 to 10.8, respectively.
The above findings suggest that antidepressant use did not influence the effectiveness of 
CPAP on depression or anxiety. Because longer treatment duration (e.g., several months 
minimum) is needed to show significant improvement in depressive symptoms, it is likely 
that the benefits of CPAP on depressive symptoms are not the direct result of eliminating 
apneic episodes and improving sleep fragmentation from short-term CPAP or oxygen 
treatment (e.g., 2–3 weeks) but may be due to its modification of the pathways linking OSA 
to depression.
Cognitive Impairment and Dementia
OSA-Related Cognitive Deficits—The prevalence of neurocognitive impairment in 
patients with OSA is not known. Deficits in attention, executive function, episodic memory, 
visuospatial and constructional abilities, and psychomotor speed have been identified, 
whereas language faculties are relatively spared.29–31 Deficits in visuospatial memory, 
information processing speed, and psychomotor function have been reported in some but not 
all studies. For example, one study of middle-aged and older adults with OSA (N = 8,059; 
ages 45–74 years; 55% women; 41% with less than high school education) reported that a 
higher AHI was associated with poorer cognitive performance on the Verbal Learning Test 
(verbal immediate and delayed recalls), the Verbal Fluency Test, and the Digit Symbol 
Test.32
OSA and the Risk of Mild Cognitive Impairment and Dementia—As part of the 
multicenter cohort study, Study of Osteoporotic Fractures, 298 elderly women (65+ years; 
mean age 82 years) enrolled in the Sleep and Cognition Study underwent overnight 
polysomnography.33 OSA (AHI ≥ 15) was diagnosed in 105 of the 298 women. Compared 
with those without OSA, patients with OSA had a higher rate of mild cognitive impairment 
or dementia (44.8% versus 31.1%; adjusted odds ratio: 1.85; 95% CI: 1.11–3.08). A cohort 
study using data from the Longitudinal Health Insurance Database in Taiwan investigated 
the relationship between OSA and dementia based on International Classification of 
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Diseases, Ninth Revision codes.34 At the 5-year follow-up, the OSA group had a 1.7-fold 
greater risk of developing dementia than the age- and sex-matched non-OSA control group 
(95% CI: 1.26–2.31; p < 0.01). Specifically, the risk for dementia in men with OSA aged 
50–59 years was 6-fold greater (95% CI: 1.96–18.90), and the risk in women with OSA aged 
70 years or over was 3.2-fold (95% CI: 1.71–6.00) greater. In the Alzheimer’s Disease 
Neuroimaging Initiative,35 onset of cognitive impairment or dementia in individuals with 
OSA was earlier than those without OSA (age at onset: 75 versus 83; χ2 = 35.03, p < 0.01). 
These data suggest that OSA may advance cognitive decline in the elderly and/or increase 
the risk of cognitive impairment or dementia.
Effects of CPAP on Cognitive Function
Studies show that adequate CPAP therapy may improve some cognitive function in patients 
with OSA. A large-scale, multicenter, randomized, double-blind cohort study, the Apnea 
Positive Pressure Long-term Efficacy Study (APPLES), investigated the effects of CPAP on 
cognitive function in patients with OSA.36 Participants were randomized to active CPAP (N 
= 556) or sham CPAP (N = 542) groups. After 2 months of treatment, performance on 
working memory significantly improved in the active CPAP group compared with the sham 
CPAP group (p < 0.01). Those with severe OSA improved more than those with mild OSA. 
However, attention/psychomotor and learning/memory functions did not improve at either 
the 2-month or 6-month follow-up.
In examining CPAP in patients with OSA and memory impairment with T-scores (T-score of 
50 represents the population mean), 58 patients with baseline mean verbal memory T-scores 
2 SDs below the mean (T-score = 30.1 ± 7.3) were enrolled.37 After 3 months of CPAP 
treatment, the average verbal memory T-score improved to approximately 1 SD below the 
mean (T-score = 38.9 ± 10.1). Those patients on CPAP for 6 hours a day (68%) showed 
significant improvement in the verbal delayed recall test (p = 0.03). The authors suggested 
that long-term memory deficits might be reversible with optimized CPAP treatment. A study 
from the Alzheimer’s Disease Neuroimaging Initiative cohort35 found that patients on CPAP 
had a later onset of mild cognitive impairment or dementia than those not on CPAP (75 
versus 83 years, p < 0.01), which was comparable with those without OSA. These data 
suggest that CPAP can protect or improve cognitive function,30,38 thus preventing or 
delaying the development of mild cognitive impairment and dementia.
BRAIN MORPHOLOGY IS CHANGED IN OSA
OSA and Cerebral Small Vessel Disease Risk
Cerebral small vessel disease (C-SVD) is a group of pathologic processes with various 
etiologies that affect small arteries and veins, arterioles, and capillaries and for which OSA 
may be an independent risk factor. C-SVD causes restricted blood flow in diseased small 
vessels, causing low perfusion pressure and hypoperfusion of the affected brain areas. In 
fact, chronic hypoperfusion appears to be responsible for development of ischemic C-
SVD.39–44 C-SVD can be identified in structural neuroimaging (T2-weighted or fluid-
attenuated inversion recovery magnetic resonance imaging [MRI]) as signal hyperintensities, 
whereas integrity of the white matter tracts can be detected by diffusion tensor MRI (DTI).
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In the first community-based study of the relationship between OSA and cerebral white 
matter morphology,45 533 older adults (age 60 ± 7.5 years) with neither cardiovascular nor 
neurologic disease underwent overnight polysomnography. Most participants (57.5%) did 
not have OSA, whereas 32% had mild and 10.5% moderate to severe OSA. The study found 
that (1) AHI was positively correlated with the severity of white matter hyperintensities 
(WMHs) on MRI (r = 0.17, p = 0.0001); (2) moderate to severe OSA was associated with 
twice the risk of having WMHs versus those without OSA (odds ratio: 2.03; 95% CI: 1.02–
4.05) after adjusting for age, sex, BMI, drinking, smoking, hyperlipidemia, and history of 
diabetes mellitus; and (3) 89% of WMHs in patients with OSA were in the frontal lobes. 
Among patients aged 65 or over (N = 120, 24% of total participants), 69% of them had more 
severe white matter changes measured by a four-point age-related white matter change 
scale46 compared with 8% of all participants. The authors suggested that moderate to severe 
OSA was an independent risk factor for the development of white matter changes in the 
middle-aged or older general population.
DTI studies also demonstrate that OSA is linked to white matter integrity 
abnormalities,47–50 whereas a further study identified functional white matter impairment in 
OSA.51 A study investigating white matter integrity changes before and after CPAP 
treatment in patients with severe OSA included 17 male patients with untreated OSA (AHI ≥ 
30) and 15 matched healthy control subjects (AHI < 5).50 Notably, these patients were 
relatively young (mean age of 43) and had a normal BMI and no medical comorbidity. Initial 
DTI demonstrated lower fractional anisotropy (a measure positively correlated with white 
matter integrity) in patients with OSA versus control subjects. Specifically, multiple areas of 
subcortical tracts of the superior and inferior parietal lobe, including the superior 
longitudinal fascicle, and of deep frontal white matter, involving the arcuate fascicle, were 
degraded. After 12 months of CPAP treatment, DTI demonstrated significant improvements 
in measures of white matter fiber integrity as well as clinical improvement in memory, 
attention, and executive functions. The authors suggested that white matter integrity 
abnormalities associated with OSA might be reversible with adequate CPAP therapy.
White Matter Changes and Depression
Substantial evidence supports an association between depression and C-SVD. Initial reports 
relating depression and subcortical WMHs seen on MRI were in elderly patients with 
depression.52,53 Compared with age- and sex-matched healthy control subjects, patients with 
depression but no history of neurologic illness had higher rates of moderate to severe deep 
and WMHs, and PVHs, and subcortical gray matter hyperintensities. The “vascular 
depression” hypothesis54 proposed that cerebrovascular disease such as C-SVD may 
predispose, precipitate, or perpetuate some geriatric depressive syndromes. Postmortem DTI 
studies supported this hypothesis, demonstrating that disruption of neural connectivity 
between subcortical structures and their frontal projections contributed to the risk of 
depression, especially when dorsolateral prefrontal cortical white matter was involved.55–57 
Vascular depression is now considered a validated subtype of depression.58,59
In a longitudinal study, the AGES-Reykjavik Study,60 1,949 participants (mean age 75 ± 5 
years; 57% women) free of dementia and depression were followed for 5 years. Baseline and 
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follow-up MRI and depressive symptoms measured with the 15-item Geriatric Depression 
Scale61 were compared. The study reported the new-onset depression rate was 10% based on 
Geriatric Depression Scale score ≥ 6 at follow-up or new use of antidepressant medication. 
The new onset of depression was found to be associated with the progression of C-SVD, 
such as an increase of volume of WMHs (p < 0.007), new Virchow-Robin spaces (p < 
0.001), new subcortical infarcts (p < 0.02), or any new infarcts (p < 0.01) after adjusting for 
cofounders, including cognitive function, demographic, and cardiovascular factors. Another 
controlled study investigated whether C-SVD–associated depression was mediated by white 
matter damage.62 Patients with evidence of C-SVD on MRI underwent additional DTI. The 
results showed that white matter damage was significantly associated with depressive 
symptoms in patients with C-SVD (β = 0.25, p = 0.03; 95% CI: 0.03–0.47). These data 
support vascular depression hypothesis.
Cerebral Microvascular Regulatory Impairment and Depression
In a prospective epidemiologic study of older adults (aged 65+ years), the Rotterdam 
Study,63 cerebral vasomotor reactivity (CVR) was measured with CO2-enhanced transcranial 
Doppler ultrasonography and depression was measured with both Center for Epidemiologic 
Studies Depression Scale (score ≥ 16) and Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision criteria for depressive disorders. At baseline, 
participants were free of a history of depression, stroke, and dementia, and the mean 
duration of follow-up was 4 years. All analyses were adjusted for sociodemographic data, 
cardiovascular risk factors, and new onset of stroke. The study found that new-onset of 
depression met both Center for Epidemiologic Studies Depression Scale score ≥ 16 and 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
criteria, including major depression, dysthymic disorder, and minor depression, and was 
associated with a reduction in mean blood flow velocity (odds ratio: 0.83; 95% CI: 0.69–
0.98; p = 0.032) and CRV (odds ratio: 0.66; 95% CI: 0.53–0.83; p < 0.001).
In a clinical study CVR was assessed with acetazolamide-enhanced, transcranial Doppler 
ultrasound in patients with major depression showing that CVR was significantly reduced in 
depressed patients compared with healthy control subjects in the absence of vascular risk 
factors (p < 0.05).64 The same group of investigators conducted a subsequent study and 
found that CVR was significantly reduced in acutely depressed patients compared with 
nondepressed control subjects. On the 21-month follow-up, CVR in the depressed group 
significantly improved with antidepressants, whereas CVR in the nondepressed control 
group remained unchanged.65 The epidemiologic and clinical data demonstrate that cerebral 
microvascular regulatory impairment plays an important role in the development of 
depression and supports the vascular depression hypothesis.63–65
Gray Matter Loss and Cognitive Impairment
Sixteen patients with newly diagnosed moderate to severe OSA (age 56 ± 7 years, 13 men) 
and 14 control subjects (age 58 ± 5 years, 9 men) underwent MRI and voxel-based 
morphometry and neuropsychological testing. Compared with control subjects, patients with 
OSA performed worse on the Verbal Learning Test (immediate and delayed recalls), the 
Stroop Test, and the Digit Span Backward Test. The density of cortical gray matter, right 
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hippocampus, and right and left caudate were decreased in patients with OSA compared 
with control subjects.66 Another study reported that regional gray matter loss, often 
unilateral, was found in multiple sites of the brain, including the frontal and parietal cortex, 
temporal lobe, anterior cingulate, hippocampus, and cerebellum. The extent of gray matter 
volume loss increases correlated positively with OSA severity.67 The hippocampal atrophy 
in older patients with OSA suggests that degenerative processes have taken place. 
Nevertheless, results from previous volumetric brain morphometry studies showed 
significant gray matter reduction in multiple cortical and subcortical regions in patients with 
OSA compared with healthy control subjects.68–71
MECHANISMS LINKING OSA TO VASCULAR DEPRESSION AND 
COGNITIVE IMPAIRMENT
OSA causes nocturnal intermittent hypoxemia and sleep fragmentation (arousals) in 
response to oxygen desaturation. Emerging evidence indicates that OSA, vascular 
depression, and cognitive impairment/dementia are linked to several pathologic processes in 
the cerebral microvascular and neurovascular systems. We present a model describing the 
key pathophysiologic mechanisms that underlie those associations for which intermittent 
hypoxia plays a critical role, including hypoperfusion, endothelial dysfunction, and 
neuroinflammation (Fig. 1).
Hypoperfusion
In OSA there are profound changes in nocturnal intracranial hemodynamics and oxygen 
saturation. During an apneic episode, cerebral blood flow velocity increases progressively 
and then drops sharply below baseline at a termination of an episode. There is a linear 
correlation between cerebral blood flow velocity and mean systemic blood pressure.72,73 In 
a healthy individual the cerebral autoregulation mechanism protects the brain by maintaining 
cerebral perfusion during blood pressure changes. However, this system is impaired in 
patients with OSA, resulting in cerebral hypoperfusion in the regions with poor collateral 
circulation, such as the terminal arterial territories.74 Chronic hypoperfusion in long 
penetrating small arteries and arterioles is likely responsible for the initial ischemic changes 
in white matter and gray matter.39
In patients with moderate to severe OSA, increased cerebral blood flow to meet the oxygen 
demand may not be able to compensate for oxygen desaturation.75,76 Thus, chronic 
hypoxemia promotes the progression of C-SVD,77 resulting in lacunar infarcts, white matter 
lesions and white matter fiber tract abnormalities, and gray matter loss.73,78 Anatomically, 
certain regions of the brain are particularly vulnerable to prolonged hypoxic-ischemic injury, 
such as the prefrontal and frontal lobes,79,80 basal ganglia,81 and hippocampus.82,83 Damage 
to these brain regions is associated with abnormal myelin and axonal integrity,84 resulting in 
mood disturbance and cognitive deficits in patients with OSA.48,66,70 There is evidence that 
prolonged hypoxic-ischemic damage to the frontal and prefrontal cortex is associated with 
executive dysfunction in patients with moderate to severe OSA47,85 that improved with 
CPAP treatment.86
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The ischemic change in cerebral microvascular structures related to depression can be 
explained by the “hypoperfusion” mechanism of vascular depression.87 This hypothesis 
suggests that impairment in hemodynamics and cerebral autoregulation leads to cerebral 
perfusion deficits, resulting in altered regional brain function and WMHs. Also, the 
“disconnection” mechanism of vascular depression suggests that damage to specific fiber 
tracts and neural circuits, especially the frontostriatal and limbic systems, results in 
disrupted neural connections that regulate mood and cognition.87 Specifically, greater 
damage to the uncinate and superior longitudinal fasciculi was associated with more severe 
depression and executive dysfunction. In addition, ischemic damage to the medial cortex and 
lateral prefrontal cortex and subcortical and temporal structures is associated with 
antidepressant treatment-resistance. Thus, OSA alone or comorbid with C-SVD may 
contribute to the development and progression of vascular depression.
Endothelial Dysfunction and CVR
In OSA repetitive intracranial blood flow surges during apneic episodes cause damage to the 
endothelial cells of small arteries and arterioles, which results in decreased endothelial 
vasodilator production (e.g., nitric oxide [NO]).88,89 NO plays a critical role in the 
regulation of cerebral blood flow in response to hypercapnia (CO2-dependent) through 
chemoregulatory mechanisms to maintain a hemostatic microenvironment.74,90,91 Because 
the availability of NO is decreased in OSA,89,92,93 the vasodilatory capacity of CVR in 
response to hypercapnia due to hypoxemia is compromised.94–96 CPAP therapy significantly 
increases circulating NO metabolites (serum nitrite/nitrate) in patients, demonstrating the 
association between OSA and CVR.89 Impaired CVR leads to poor microvascular blood 
flow during apneas and hypopneas, resulting in the development or progression of deep and 
periventricular WMHs and high grades of deep and periventricular white matter lesions 
(e.g., grades 2 and 3) according to the Fazekas scale.97,98 These evidence suggests that NO 
plays a crucial role in acute hemodynamic regulation and long-term vascular remodeling in 
OSA.89
Epidemiologic and clinical studies have shown that reduced cerebral blood flow because of 
impaired CVR is a risk factor for depression in the absence of cardiovascular risk factors, 
cardiac disease, and stroke.63–65,99 Because OSA causes impaired CVR and subsequent 
ischemic damage of white matter and white matter fiber tracts, OSA is a risk factor for 
vascular depression in some patients. Treatment of OSA may prevent further damage to 
cerebral small arteries and arterioles, which may reduce the risk of developing or 
exacerbating vascular depression.
In OSA the disruption of NO pathways causes a cascade of neuronal metabolic deficiencies, 
resulting in destabilizing neurons, synapses, and neurotransmission, which in turn leads to 
synaptic loss and neuronal damage.100,101 In some patients depleted NO leads to the 
neurodegenerative state characterized by the formation of amyloid angiopathy, senile 
plaques, and neurofibrillary tangles.102,103 Thus, OSA may contribute to the development of 
cognitive impairment as well as depression.
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Blood–Brain Barrier and Neuroinflammation
In OSA repetitive hypoxia and reoxygenation stimulates endothelial cells to produce 
excessive reactive oxygen species, especially during reoxygenation, which promotes 
oxidative stress.104,105 Oxidative stress causes BBB hyperpermeability106 and 
neuroinflammation,107 resulting in plasma proteins leaking into the arteriolar walls and 
perivascular spaces (Virchow-Robin spaces).108 A consequence of this is the accumulation 
of macrophages and fibrosis in the arteriolar walls, leading to the development or 
progression of C-SVD, which can cause white matter damage and lacunar infarction.109,110 
Also, accumulation of plasma proteins (e.g., Aβ amyloid) in the small arterial walls and 
perivascular space results in neurotoxicity, which initiates the onset or contributes to the 
progression of neurodegeneration.111–113 Finally, inflammation at the blood–brain barrier 
(BBB) leads to altered transport of molecules across the barrier, resulting in progressive 
synaptic plasticity and neuronal dysfunction and loss.114,115 Together, OSA may play an 
important role in the pathogenesis of depression and cognitive impairment through 
neuroinflammation and BBB hyperpermeability.
CONCLUSIONS
OSA may initiate or amplify the pathologic processes of C-SVD and BBB dysfunction, 
resulting in the development or exacerbation of depressive symptoms and cognitive deficits. 
In elderly patients with vascular risk factors, OSA may put further stress on the already 
compromised cerebral microvascular and neurovascular systems. Given the evidence that 
adequate treatment of OSA with CPAP improves depression and neurocognitive functions, it 
is important to identify OSA when assessing patients with depression or cognitive 
impairment.
RECOMMENDATIONS FOR CLINICIANS
Patients may have OSA symptoms for years and yet remain undiagnosed. In many cases 
because symptoms of depression overlap with symptoms of OSA, treating the depression 
may cause OSA to be overlooked.116 Patients with untreated OSA may present to 
psychiatric clinics with complaints of sleep disturbances, daytime sleepiness, fatigue, 
increased irritability or agitation, and chronically depressed mood. In middle-aged and older 
adults with a subjective cognitive decline and clinical evidence of cognitive impairment and 
dementia, clinicians should routinely inquire about OSA symptoms.
Several validated questionnaires are available for screening for OSA in clinical settings, such 
as the Berlin and Stop-Bang questionnaires.117 The Berlin screening questionnaire118 is 
most commonly used. It assess the severity of snoring, fatigue, and hypertension. The Stop-
Bang questionnaire has the highest methodologic quality and sensitivity in predicting 
moderate (AHI ≥ 15) and severe (AHI ≥ 30) OSA.117 The Stop-Bang has eight yes/no 
questions: STOP (loud Snore, Tired, Observed apnea, and high blood Pressure) and BANG 
(BMI, Age, Neck size, and Gender).119,120 Patients with a high probability of having OSA 
on screening should receive a comprehensive sleep evaluation by a sleep specialist.
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Among primary sleep disorders, OSA causes the most serious morbidity and mortality. 
There is strong evidence that patients with untreated moderate to severe OSA have increased 
rates of depression, cognitive impairment, and dementia. Clinical studies have demonstrated 
that treatment for OSA (e.g., CPAP and oxygen therapy) improves cerebral microvascular 
perfusion and oxygenation, reduces vascular inflammatory and immune responses, and 
repairs BBB functionality. Therefore, successful treatment of OSA may prevent further 
cerebral microvascular and neurovascular damage. Large-scale studies are needed to 
examine whether treatment of OSA changes the deteriorating trajectory of elderly patients 
with depression, cognitive impairment, and dementia.
Studies are needed to elucidate the impact of OSA on the development of, treatment 
response to, and prognosis of vascular depression and cognitive impairment. Treatment of 
OSA improves cerebral microvascular perfusion, oxygenation, and hypertension and reduces 
vascular inflammatory responses and thus may reduce further cerebral microstructure 
damage. It is compelling to study whether the effective treatment of OSA prevents the 
development of depression and cognitive impairment and/or changes the deteriorating 
trajectory of patients with vascular depression, cognitive impairment, and dementia.
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